Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

LB-102

Small molecule · developed by LB Pharmaceuticals

Phase 3 Most advanced trial
2 Registered trials

What is LB-102?

LB-102 is an oral tablet studied in schizophrenia, given at flexible doses of 50 mg to 100 mg over six weeks in the trial sources.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type
Small molecule
Therapy area
Psychiatry
Developer
LB Pharmaceuticals Inc.
In trials of
LBRX
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 3

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT07369154 Phase 3 Schizophrenia Recruiting LBRX
NCT07363577 Phase 3 Schizophrenia Recruiting LBRX

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Schizophrenia

Sources

Updated Oct 18, 2026.

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.